Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile

Antiviral Research

Volumn 71, Issue 1, 2006, Pages 15-23

  de Castro, Sonia ^a   García Aparicio, Carlos ^a   Van Laethem, Kristel ^b   Gago, Federico ^c   Lobatón, Esther ^a   De Clercq, Erik ^b   Balzarini, Jan ^b   Camarasa, María José ^a   Velázquez, Sonsoles ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Deaminated TSAO; Non nucleoside HIV 1 RT inhibitors; Spironucleosides; TSAO compounds

Indexed keywords

[1 [2',5' BIS O (TERT BUTYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 3 N METHYLTHYMINE] 3' SPIRO 5'' (4'' AMINO 1'',2'' OXATHIOLE 2'',2'' DIOXIDE)NUCLEOSIDE; ANTIVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; LAMIVUDINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; QUINOXALINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DEAMINATION; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; VIRUS CULTURE; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HIV-2; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPIRO COMPOUNDS; THYMIDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33746974786     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.02.009     Document Type: Article

References (39)

1. Auwerx J., Stevens M., Van Rompay A.R., Bird L.E., Ren J., De Clercq E., Öberg B., Stammers D.K., Karlsson A., and Balzarini J. The phenylmethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type 2 RT. J. Virol. 78 (2004) 7427-7437
2. Balzarini J., Pérez-Pérez M.J., San-Félix A., Schols D., Perno C.F., Vandamme A.M., Camarasa M.J., and De Clercq E. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro- 5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4392-4396
3. Balzarini J., Karlsson A., Pérez-Pérez M.-J., Camarasa M.-J., Tarpley W.G., and De Clercq E. Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. 67 (1993) 5353-5359
4. Balzarini J., Karlsson A., Vandamme A.M., Pérez-Pérez M.J., Zhang H., Vrang L., Öberg B., Backbro K., Unge T., San-Félix A., Velázquez S., Camarasa M.J., and De Clercq E. Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro- 5″-(4″-amino-1″,2″-oxathiole-2″,2″ -dioxide)]-β-d-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 6952-6956
5. Balzarini J., Velázquez S., San-Félix A., Karlsson A., Pérez-Pérez M.J., Camarasa M.J., and De Clercq E. The HIV-l-specific TSAO-purine analogues show a resistance spectrum that is different from that of the HIV-l-specific non-nucleoside analogues. Mol. Pharmacol. 43 (1993) 109-114
6. Balzarini J., Kleim J.-P., Riess G., Camarasa M.-J., De Clercq E., and Karlsson A. Sensitivity of (138 Glu → Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochem. Biophys. Res. Commun. 201 (1994) 1305-1312
7. Balzarini J. Suppression of resistance to drug targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem. Pharmacol. 58 (1999) 1-27
8. Balzarini J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr. Top. Med. Chem. 4 (2004) 921-944
9. Cadogan J.I.G., and Molina G.A. A simple and convenient deamination of aromatic amines. J. Chem. Soc., Perkin I (1973) 541-542
10. Camarasa M.J., Pérez-Pérez M.J., San-Félix A., Balzarini J., and De Clercq E. 3′-Spironucleosides a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-xylo and ribofuranose]-3′-spiro-5″-[4″-amino-1″,2″- oxathiole-2″,2″-dioxide] (TSAO) pyrimidine nucleosides. J. Med. Chem. 35 (1992) 2721-2727
11. Camarasa M.J., Jimeno M.L., Pérez-Pérez M.J., Alvarez R., Velázquez S., and Lozano A. Synthesis, NMR studies and theoretical calculations of novel 3-spiro-branched ribofuranoses. Tetrahedron 55 (1999) 12187-12200
12. Camarasa M.-J., San-Félix A., Velázquez S., Pérez-Pérez M.-J., Gago F., and Balzarini J. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Curr. Top. Med. Chem. 4 (2004) 945-963
13. Campiani G., Ramunno A., Maga G., Nacci V., Fattorusso C., Catalanotti B., Morelli E., and Novellino E. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present and future perspectives. Curr. Pharm. Design 8 (2002) 615-657
14. Coulter J.M., Lewis J.W., and Lynch P.P. Hydrogenolisis of enamines. Tetrahedron 24 (1968) 4489-4500
15. de Castro S., Lobatón E., Pérez-Pérez M.J., San-Félix A., Cordeiro A., Andrei G., Snoeck R., De Clercq E., Balzarini J., Camarasa M.J., and Velázquez S. Novel TSAO derivatives with anti-HIV-1 and HCMV activity. J. Med. Chem. 48 (2005) 1158-1168
16. De Clercq E. The role of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res. 38 (1998) 153-179
17. De Clercq E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Il Farmaco 54 (1999) 26-45
18. Drake S.M. NNRTIs-a new class of drugs for HIV. J. Antimicrob. Chemoth. 45 (2000) 615-657
19. Driscoll J.S., Siddiqui M.A., Ford Jr. H., Kelley J.A., Roth J.S., Mitsuya H., Tanaka M., and Marquez V.E. Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 6-Amino prodrugs of 2′-β-fluoro-2′,3′-dideoxyinosine. J. Med. Chem. 36 (1996) 1619-1625
20. Engel A. Houben-Weyl Methoden der Organischen Chemie, vol. E 16 a/2 (1990), Georg Thieme, Stuttgart p. 1052
21. Esnouf R.M., Ren J., Hopkins A.L., Ross C.K., Jones E.Y., Stammers D.K., and Stuart D.I. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 3984-3989
22. Fujiwara T., Sato A., El-Farrash M., Miki S., Abe K., Isaka Y., Kodama M., Wu Y., Chen L.B., Harada H., Sugimoto H., Hatanaka M., and Hinuma Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 42 (1998) 1340-1345
23. Jonckheere H., Taymans J.M., Balzarini J., Velázquez S., Camarasa M.J., Desmyter J., De Clercq E., and Anne J. Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro- 5″-(4″-amino-1″,2″-oxathiole-2″,2″ -dioxide)] (TSAO) derivatives is determined by the mutation Glu138 → Lys on the p51 subunit. J. Biol. Chem. 269 (1994) 25255-25258
24. Jonckheere H., Anné J., and De Clercq E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. (2000) 129-154
25. Lobatón E., Rodríguez-Barrios F., Gago F., Pérez-Pérez M.J., De Clercq E., Balzarini J., Camarasa M.J., and Velázquez S. Synthesis of 3″-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach. J. Med. Chem. 45 (2002) 3934-3945
26. Nair V., and Richardson S.G. Utility of purinyl radicals in the synthesis of base-modified nucleosides and alkylpurines: 6-amino group replacement by H, Cl, Br and I. J. Org. Chem. 45 (1980) 3969-3974
27. Pandey P.K., Kaushik N., Talele T.T., Yadav P.N., and Pandey V.N. The beta7-beta8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. Biochemistry 40 (2001) 9505-9512
28. Pandey P.K., Kaushik N., Singh K., Sharma B., Upadhyay A.K., Kumar S., Harris D., and Pandey V.N. Insertion of a small peptide of six amino acids into the beta7-beta8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochem. 3 (2002) 18-31
29. Pelemans H., Aertsen A., Van Laethem K., Vandamme A.-M., De Clercq E., Pérez-Pérez M.J., San-Félix A., Velázquez S., Camarasa M.J., and Balzarini J. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138. Virology 280 (2001) 97-105
30. Pérez-Pérez M.J., San-Félix A., Balzarini J., De Clercq E., and Camarasa M.J. TSAO Analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-ribofurano syl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole -2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 35 (1992) 2988-2995
31. Restle T., Müller B., and Goody R.S. Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. J. Biol. Chem. 265 (1990) 8986-8988
32. Restle T., Müller B., and Goody R.S. RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms. FEBS Lett. 300 (1992) 97-100
33. Rodríguez-Barrios F., Pérez C., Lobatón E., Velázquez S., Chamorro C., San-Félix A., Pérez-Pérez M.J., Camarasa M.J., Pelemans H., Balzarini J., and Gago F. Identification of a putative binding site for [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosy l]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2 ″,2″-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. J. Med. Chem. 44 (2001) 1853-1865
34. Ren J., Diprose J., Warren J., Esnouf R.M., Bird L.E., Ikemizu S., Slater M., Milton J., Balzarini J., Stuart D.I., and Stammers D.K. Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analices. J. Biol. Chem. 275 (2000) 5633-5639
35. Sluis-Cremer N., Dmitrienko G.I., Balzarini J., Camarasa M.J., and Parniak M.A. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro[4″-amino-2″,2″-dioxo-1″,2″-oxathi ole-5″,3′-[2′,5′-bis-O-(tert-butyldimethylsilyl) -β-d-ribofuranosyl]]]-3-ethylthymine. Biochemistry 39 (2000) 1427-1433
36. Tavel J.A., Miller K.D., and Masur H. Guide to major clinical trials of antiretroviral therapy in human inmunodeficiency virus-infected patients: protease inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors. Clin. Infect. Dis. 28 (1999) 643-676
37. Vandamme A.-M., Van Laethem K., Van Vaerenbergh E., and De Clercq E. Anti-HIV virus combination therapy and resistance management. Int. Antiviral News 6 (1998) 182-187
38. Vasudevachari M.B., Battista C., Lane H.C., Psallidopoulos M.C., Zhao B., Cook J., Palmer J.R., Romero D.L., Tarpley W.G., and Salzman N.P. Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology 190 (1992) 269-277
39. Vorbrüggen H., Krolikiewicz K., and Bennua B. Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts. Chem. Ver. 114 (1981) 1234-1256